Blueweave
Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market- Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028, Segmented By Treatment (Drug Class [Alpha-Blockers, 5-Alpha-reductase Inhibitors, Phosphodiesterase-5 Enzyme Inhibitor, Muscarinic Receptor Antagonist, Combination Drug], Minimally Invasive Surgeries [Transurethral Resection of the Prostate, Transurethral Incision of the Prostate, Robotic Surgeries, Transurethral Microwave Thermotherapy, Prostatic Urethral Lift, Others], Laser Therapy, Others]), By Therapy (Mono Drug Therapy, Combination drug Therapy), By End User (Hospitals, Home and Healthcare, Ambulatory Surgical Centers, Others) By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa)

  • Published Date: August 2022
  • Report ID: BWC22256
  • Available Format: PDF
  • Page: 240

Report Overview

The ageing of the population, increased awareness of prostate cancer and its treatment, technological breakthroughs in personalized medicine, rising use of minimally invasive treatments, and bettering global healthcare infrastructure are the main drivers of market expansion. Benign prostatic hyperplasia (benign prostatic hyperplasia) is an enlargement of the prostate gland that is not malignant. Other names for this ailment are benign prostatic blockage and benign prostatic obstruction. It is one of the most prevalent illnesses among males over 50.

Global Benign Prostatic Hyperplasia Treatment Market - Industry Trends & Forecast Report 2028

Global benign prostatic hyperplasia treatment market was worth USD 11.25 billion in 2021 and is further projected to reach USD 17.69 billion by the year 2028, exhibiting a CAGR of 6.8% during 2022-2028 (forecast period). The rise in benign prostatic hyperplasia prevalence and the expanding worldwide male geriatric population are both important factors driving the growth of the benign prostatic hyperplasia treatments market. In addition, increased sympathetic nerve activity, altered endocrine state, a heightened inflammatory response, and oxidative stress all have a role in the development of benign prostatic hyperplasia in obese individuals. The body's hormonal fluctuations also contribute to benign prostatic hyperplasia by causing prostate enlargement. As a result, this fuels the market for treatments for benign prostatic hyperplasia.

Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market Overview

Age causes the prostate to enlarge as a man gets older. The urethra is pinched and pressed upon by the prostate gland as it expands. The bladder's lining thickens. The blockage that develops worsens detrusor muscle response and raises urine outflow resistance. Problems starting to urinate, a weak urine stream, a difficulty to empty the bladder, and increased urination frequency—typically at night—are all symptoms of this illness. Benign prostatic hyperplasia (benign prostatic hyperplasia) is an enlargement of the prostate gland that is not malignant.

Other names for this ailment are benign prostatic blockage and benign prostatic obstruction. It is one of the most prevalent illnesses among males over 50. The hyperplastic alterations in the prostate tissue that lead to prostatic enlargement are the root cause of benign prostatic hyperplasia symptoms. The risk of various conditions also rises in the presence of benign prostatic hyperplasia. Lower urinary tract infections, the most frequent condition brought on by benign prostatic hyperplasia, are treated with alpha-blockers as the first line of protection. However, there are more medications on the market that provide relief from the signs and symptoms of benign prostatic hyperplasia.

Global Benign Prostatic Hyperplasia Treatment Market Forecast and Trends

Growth Driver

Prevalence of Benign Prostatic Hyperplasia is Rising

Benign prostatic hyperplasia is a common reason why men have symptoms of the lower urinary tract. benign prostatic hyperplasia is regarded as a typical aspect of male ageing and is hormonally reliant on the generation of testosterone and dihydrotestosterone (DHT). By the age of 60, approximately 50% of men have histopathologic benign prostatic hyperplasia, and by the age of 85, 90% have. As benign prostatic hyperplasia is a typical disease that manifests in men throughout the ageing process, the ageing population expansion, particularly the geriatric male segment, may be viewed as a significant cause of benign prostatic hyperplasia incidence. Thus, as this demographic group expands, there will be a demand for suitable treatments in important markets.

Restraint                                                                                                                 

The Negative Effects of Benign Prostatic Hyperplasia Medicine

Although benign prostatic hyperplasia may be treated with medication and surgery, both procedures have serious negative effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other medication groups are frequently used to treat benign prostatic hyperplasia. Alpha-blockers frequently cause rhinitis, retrograde ejaculation, orthostatic hypotension, and dizziness as adverse effects. The elderly is particularly vulnerable to the serious morbidities of dizziness and orthostatic hypotension, which include falls and consequent injuries. Among other 5-ARIs, finasteride and dutasteride convert testosterone to dihydrotestosterone. These medications also lessen the production of a number of neuroactive hormones, although they may cause depression by altering the neuroendocrine stress response. Gynecomastia, impotence, diminished libido, and ejaculate volume are additional negative effects of 5-ARIs.

Impact of COVID-19 on the Global Benign Prostatic Hyperplasia Treatment Market

Governments in a number of countries have implemented lockdowns and social seclusion to safeguard residents as a result of the COVID-19 pandemic. Manufacturers of benign prostatic hyperplasia medications and surgical equipment have been negatively impacted by the global economic crisis brought on by the pandemic. Furthermore, the government's restrictions on domestic and international commerce to stop the virus' spread have had a substantial impact on the supply of raw materials. Due to a lack of raw materials, this further hampered the growth of the benign prostatic hyperplasia treatment market by having an impact on the production of active pharmaceutical ingredients (APIs).

Global Benign Prostatic Hyperplasia Treatment Market – By Treatment

The benign prostatic hyperplasia treatment market is divided into treatment including drug class, minimally invasive surgeries, laser therapy, and others. The largest and fastest-growing market sector in this area is drug treatment. Due to the fact that medications are typically favoured as the first line of therapy for benign prostatic hyperplasia, this sector had the biggest market share. This was mostly caused by the widespread use of medications for the acute and subacute stages of the disorder's management and treatment. In addition, prescription drugs are given for post-operative care, which raises their use rate in comparison to surgical instruments.

Global Benign Prostatic Hyperplasia Treatment Market – By End User

Based on the end user, hospitals and clinics, home healthcare, and other segments are included in the market. Home and healthcare make up the majority of this market as most patients are advised to take medications rather than undergo surgery. For a few weeks after surgery, patients should keep taking their prescribed medications. Due to this, home healthcare is prioritised above hospital treatment in the market. Since most patients are recommended to take drugs rather than undergo surgery, therefore home healthcare accounted for the greatest proportion.

Global Benign Prostatic Hyperplasia Treatment Market– By Regional Insights

Based on region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, the Asia-Pacific, Latin America, the Middle East & Africa, and the Rest of the World. The market for treating benign prostatic hyperplasia was dominated by North America. With the rising activities of leading players, the increase in the percentage of elderly and obese people, and the accessibility of research funding are the main drivers fuelling the market's expansion. These factors may be credited for the huge share of this market segment.

North America held the largest market share for benign prostatic hyperplasia therapies globally, and it is projected that it will continue to hold this position during the forecast period. This is due to an increase in benign prostatic hyperplasia prevalence, unhealthy lifestyles that cause obesity, the presence of important actors, and rising healthcare costs in the area. However, due to the region's growing elderly population, rising R&D activities, rise in urological disorders, unmet medical needs, and increased investments in the healthcare industry, Asia-Pacific is expected to see significant growth.

Competitive Landscape

The major players operating in this market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Sanofi, and other prominent players. Based on a variety of factors, including company background, financial overview, wavelength type, business strategies, and recent advances, these companies continue to lead the market. The companies have adopted several strategies including engaging in strategic alliances, agreements, mergers, and collaborations.

 

Recent Development

 

  • In January 2021: Pharex Tamsulosin for the treatment of benign prostatic hyperplasia was introduced by PHAREX Health Corporation in collaboration with the Philippine Urological Association (PUA).

Scope of Report:

Attribute   Details  
Years Considered   Historical data- 2018-2021
Base Year- 2021
Forecast- 2022-2028
Facts Covered   Revenue in USD Billion  
Market Coverage   United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, United Arab Emirates, South Africa  
Product/Service Segmentation   By Treatment, By Therapy, by End user, and by Region.
Key Players   The key players dominating the global Benign prostatic hyperplasia market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Sanofi, and other prominent players.

 

By Treatment

  • Drug Class
  1. Alpha-blockers
  2. Alpha-reductase Inhibitor (5-ARIs)
  3. Phosphodiesterase-5 Enzyme Inhibitor
  4. Muscarinic Receptor Antagonist (MRA)
  5. Combination Drug
  • Minimally Invasive Surgeries
  1. Transurethral Resection of the Prostate (TURP)
  2. Transurethral Incision of the Prostate (TUIP)
  3. Robotic Surgeries
  4. Transurethral Microwave Thermotherapy (TUMT)
  5. Prostatic Urethral Lift
  6. Others
  • Laser Therapy
  • Others

By Therapy

  • Mono drug therapy
  • Combination drug therapy

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  1. Research Framework
    1. Research Objective
    2. Product Overview

1.3 Market Segmentation

  1. Research Methodology
    1. Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents
    5. Assumption & Limitation
    6. Analyst tools and models
  2. Executive Summary
  3. Global Benign Prostatic Hyperplasia Treatment Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
    3. Technological Advancement/Recent Development
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Benign Prostatic Hyperplasia Treatment Market Overview
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
        1. Drug Class
          1. Alpha-blockers
          2. Alpha-reductase Inhibitor (5-ARIs)
          3. Phosphodiesterase-5 Enzyme Inhibitor
          4. Muscarinic Receptor Antagonist (MRA)
          5. Combination Drug
        2. Minimally Invasive Surgeries
          1. Transurethral Resection of the Prostate (TURP)
          2. Transurethral Incision of the Prostate (TUIP)
          3. Robotic Surgeries
          4. Transurethral Microwave Thermotherapy (TUMT)
          5. Prostatic Urethral Lift
          6. Others
        3. Laser Therapy
        4. Others
      2. By Therapy
        1. Mono Drug Therapy
        2. Combination Drug Therapy
      3. By End User
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Specialty Clinics
        4. Others
      4. By Region
        1. North America
        2. Europe
        3. The Asia Pacific
        4. Latin America
        5. The Middle East and Africa
  5. North America Benign Prostatic Hyperplasia Treatment Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
      2. By Therapy
      3. By End User
      4. By Country
        1. United States
        2. Canada
  6. Europe Benign Prostatic Hyperplasia Treatment Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
      2. By Therapy
      3. By End User
      4. By Country
        1. Germany
        2. United Kingdom
        3. Italy
        4. France
        5. Spain
        6. The Netherlands
        7. Rest of Europe
  7. The Asia Pacific Benign Prostatic Hyperplasia Treatment Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
      2. By Therapy
      3. By End User
      4. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Australia
        6. Indonesia
        7. Malaysia
        8. Rest of Asia Pacific
  8. Latin America Benign Prostatic Hyperplasia Treatment Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
      2. By Therapy
      3. By End User By Country
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  9. The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Treatment
      2. By Therapy
      3. By End User
      4. By Country
        1. Saudi Arabia
        2. UAE
        3. Qatar
        4. Kuwait
        5. South Africa
        6. Egypt
        7. Nigeria
        8. Rest of Middle East & Africa
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
  11. Impact of COVID-19 on Global Benign Prostatic Hyperplasia Treatment Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. Abbott Laborites
    2. Allergan plc
    3. Astellas Pharma, Inc.
    4. Asahi Kasei Corporation
    5. Boehringer Ingelheim GmbH
    6. GlaxoSmithKline plc
    7. Pfizer, Inc.
    8. Boston Scientific Corporation
    9. Teleflex Incorporated
    10. Endo International plc
    11. Urologix, LLC
    12. LISA Laser
    13. Olympus Corporation
    14. Teva Pharmaceutical Industries Ltd.
    15. Merck & Co., Inc.
    16. Sanofi
  13. Key Strategic Recommendations

 

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Figure 1        Global Benign Prostatic Hyperplasia Treatment Segmentation

Figure 2        Global Benign Prostatic Hyperplasia Treatment Market Value Chain Analysis

Figure 3        Company Market Share Analysis, 2021

Figure 4        Global Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 5        Global Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 6        Global Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 7        Global Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

Figure 8       North America Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 9        North America Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 10       North America Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 11       North America Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

Figure 12       Europe Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 13       Europe Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 14       Europe Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 15       Europe Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

Figure 16       Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 17       Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 18       Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 19       Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

Figure 20       Latin America Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 21       Latin America Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 22       Latin America Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 23       Latin America Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

Figure 24       The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size, By Treatment (USD Million), 2018-2028

Figure 25       The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share, By Therapy, 2018-2028

Figure 26       The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share, By End User, By Value, 2018-2028

Figure 27       The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share, By Region, By Value, 2018-2028

 

List of Tables

 

Table 1         Global Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 2         Global Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 3         Global Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 4         Global Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 5         North America Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 6         North America Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 7         North America Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 8         North America Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 9         Europe Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 10        Europe Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 11        Europe Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 12        Europe Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 13        Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 14        Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 15        Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 16        Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 17        Latin America Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 18        Latin America Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 19        Latin America Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 20        Latin America Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 21        The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size, By Treatment, By Value, 2018-2028

Table 22        The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size, By Therapy Mode, By Value, 2018-2028

Table 23        The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size, By End User, By Value, 2018-2028

Table 24        The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size, By Region, By Value, 2018-2028

Table 25        Abbott Laboratories Company Overview

Table 26        Abbott Laboratories Financial Overview

Table 27        Allergan plc Company Overview

Table 28        Allergan plc Financial Overview

Table 29        Astellas Pharma, Inc. Company Overview

 

Table 30        Astellas Pharma, Inc. Financial Overview

 

Table 31        Asahi Kasei Corporation Company Overview

 

Table 32        Asahi Kasei Corporation Financial Overview

 

Table 33        Boehringer Ingelheim GmbH Company Overview

 

Table 34        Boehringer Ingelheim GmbH Financial Overview

 

Table 35        GlaxoSmithKline plc Company Overview

 

Table 36        GlaxoSmithKline plc Financial Overview

 

Table 37        Pfizer, Inc. Company Overview

 

Table 38        Pfizer, Inc. Financial Overview

 

Table 39        Boston Scientific Corporation Company Overview

 

Table 40        Boston Scientific Corporation Financial Overview

 

Table 41        Teleflex Incorporated Company Overview

 

Table 42        Teleflex Incorporated Financial Overview

 

Table 43        Endo International plc Company Overview

 

Table 44        Endo International plc Financial Overview

 

Table 45        Urologix, LLC Company Overview

 

Table 46        Urologix, LLC Financial Overview

 

Table 47        LISA Laser Company Overview

 

Table 48        LISA Laser Financial Overview

 

Table 49        Olympus Corporation Company Overview

 

Table 50        Olympus Corporation Financial Overview

 

Table 51        Teva Pharmaceutical Industries Ltd. Company Overview

 

Table 52        Teva Pharmaceutical Industries Ltd. Financial Overview

 

Table 51        Merck & Co., Inc. Company Overview

 

Table 52        Merck & Co., Inc. Financial Overview

 

Table 51        Sanofi Company Overview

 

Table 52        Sanofi Financial Overview

Market Segmentation

By Treatment

  • Drug Class
  1. Alpha-blockers
  2. Alpha-reductase Inhibitor (5-ARIs)
  3. Phosphodiesterase-5 Enzyme Inhibitor
  4. Muscarinic Receptor Antagonist (MRA)
  5. Combination Drug
  • Minimally Invasive Surgeries
  1. Transurethral Resection of the Prostate (TURP)
  2. Transurethral Incision of the Prostate (TUIP)
  3. Robotic Surgeries
  4. Transurethral Microwave Thermotherapy (TUMT)
  5. Prostatic Urethral Lift
  6. Others
  • Laser Therapy
  • Others

By Therapy

  • Mono drug therapy
  • Combination drug therapy

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The global benign prostatic hyperplasia treatment market reached USD 11.25 billion in 2021.
Ans: The rise in benign prostatic hyperplasia prevalence and the expanding worldwide male geriatric population are the major factors driving the growth of the benign prostatic hyperplasia treatment market.
Ans: The major players operating in this market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Sanofi, and other prominent players.
Ans: Hospital segment accounted for the largest share in the global benign prostatic hyperplasia treatment market.
Ans: North America region accounted for the largest share in the global benign prostatic hyperplasia market.